Study S001622

Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01254123
Acronym: EXAMI
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: SINGLE
Status: UNKNOWN
Enrollment: 40
Start: 2009-11
Lead sponsor: Amsterdam UMC, location VUmc
Conditions: Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).
Interventions: DRUG:Exenatide infusion; DRUG:Placebo infusion.
Results posted: FALSE

Registered primary outcomes

Safety of GLP-1 receptor agonist Exenatide infusion compared to placebo in patients with an acute myocardial infarction undergoing primary PCI []

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025816	Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials. Huang M, Annals of medicine	2017	Systematic review	PMID 28286967 DOI	cites ClinicalTrials.gov:NCT01254123; registry reference DERIVED:28286967
R0017401	Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial. Scholte M, Trials	2011	Protocol	PMID 22067476 DOI	cites ClinicalTrials.gov:NCT01254123; registry reference DERIVED:22067476